Novel anticonvulsants in the treatment of alcoholism
- PMID: 15882114
- DOI: 10.1517/13543784.14.4.371
Novel anticonvulsants in the treatment of alcoholism
Abstract
There have been many recent developments in the pharmacological management of alcohol withdrawal and alcohol dependence. Although previous treatments had included benzodiazepines as their mainstay, the use of these agents in the alcoholic population is problematic. Benzodiazepines are themselves addictive and they may increase the risk of alcohol relapse. Non-benzodiazepine anticonvulsants such as carbamazepine, valproic acid, gabapentin, vigabatrin and topiramate have been shown to be excellent treatments of both alcohol withdrawal and the prevention of alcohol relapse. Although none of these agents have yet been approved by the FDA, there is growing evidence in the literature to support their use.
Similar articles
-
Treatment of alcohol withdrawal syndrome with carbamazepine, gabapentin, and nitrous oxide.Am J Health Syst Pharm. 2008 Jun 1;65(11):1039-47. doi: 10.2146/ajhp070284. Am J Health Syst Pharm. 2008. PMID: 18499876 Review.
-
A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm.Alcohol Clin Exp Res. 2007 Feb;31(2):221-7. doi: 10.1111/j.1530-0277.2006.00299.x. Alcohol Clin Exp Res. 2007. PMID: 17250613 Clinical Trial.
-
New developments in the pharmacotherapy of alcohol dependence.Am J Addict. 2001;10(s1):s3-s15. doi: 10.1080/10550490150504092. Am J Addict. 2001. PMID: 11268820 Review.
-
Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.J Clin Psychiatry. 2007 Nov;68(11):1691-700. doi: 10.4088/jcp.v68n1108. J Clin Psychiatry. 2007. PMID: 18052562 Clinical Trial.
-
An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants.Addict Behav. 2006 Sep;31(9):1628-49. doi: 10.1016/j.addbeh.2005.12.029. Epub 2006 Feb 10. Addict Behav. 2006. PMID: 16472931 Review.
Cited by
-
Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking.Alcohol. 2017 Feb;58:33-45. doi: 10.1016/j.alcohol.2016.05.007. Epub 2016 Jun 27. Alcohol. 2017. PMID: 27432260 Free PMC article.
-
Gabapentin combined with naltrexone for the treatment of alcohol dependence.Am J Psychiatry. 2011 Jul;168(7):709-17. doi: 10.1176/appi.ajp.2011.10101436. Epub 2011 Mar 31. Am J Psychiatry. 2011. PMID: 21454917 Free PMC article. Clinical Trial.
-
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.Alcohol Clin Exp Res. 2012 Aug;36(8):1421-30. doi: 10.1111/j.1530-0277.2011.01716.x. Epub 2012 Feb 10. Alcohol Clin Exp Res. 2012. PMID: 22324516 Free PMC article. Clinical Trial.
-
Novel anticonvulsants for reducing alcohol consumption: A review of evidence from preclinical rodent drinking models.OA Alcohol. 2013 Feb 1;1(1):2. doi: 10.13172/2053-0285-1-1-446. OA Alcohol. 2013. PMID: 24432188 Free PMC article.
-
Intermittent hypoxia training: Powerful, non-invasive cerebroprotection against ethanol withdrawal excitotoxicity.Respir Physiol Neurobiol. 2018 Oct;256:67-78. doi: 10.1016/j.resp.2017.08.007. Epub 2017 Aug 12. Respir Physiol Neurobiol. 2018. PMID: 28811138 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical